Entries by oslocancer

Four Cluster Companies Get Innovation Reward

Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations! Important with early financing Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. […]

Precision Medicine has a New Target

Researchers at the Centre for Cancer Biomedicine, a Center of Excellence and a member of Oslo Cancer Cluster, have discovered an enzyme wreaking havoc inside cells that turns into tumors. For our body to work as normal, cells need to know which way is up. When cells lose track of their orientation, they can start […]

Raising Prostate Cancer Awareness

This week on Monday, Prostate Cancer Day, the Norwegian Cancer Society initiated their Blue-Ribbon Campaign to raise prostate cancer awareness. In line with the campaign, Oslo Cancer Cluster gives you the chance to update yourselves on prostate cancer research Thursday the 30th of November.   The Blue-Ribbon campaign is initially a month’s focus on prostate […]

New Funds for Ultimovacs

Investors are recognizing the huge potential of Oslo Cancer Cluster member Ultimovacs. They are currently investing an additional 125 million NOK in the cancer research company.   Well known investors and Ultimovacs backers Stein Erik Hagen, Anders Wilhelmsen og Bjørn Rune Gjelsten are among financiers putting fresh money into the cancer research company, according to […]

Photocure with FDA Priority

Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview.   The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device […]

KUR: En reise langs det elektromagnetiske spekteret

I kursserien Kompetanseutvikling i realfag (KUR), spør vi denne gangen: Er det farlig med stråling? Hvordan påvirkes vi av trådløse nettverk?  Hvordan behandler man kreft med ioniserende stråling? Stråling er en del av hverdagen vår på mange måter.  Det elektromagnetiske spekteret er også en gjenganger i mange læreplaner, både grunnskolen og i videregående skole.  Denne kurskvelden har […]

Roche Medicine Ready to Fight Breast Cancer

On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway. The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, […]

Nominated as “Norway’s smartest industrial company”

Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday. The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad.  Thermo Fisher Scientific is one […]

Kronikk i Aftenposten: De nordiske landene kan gjøre noe resten av verden drømmer om

De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars. Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og […]

Targovax to present at upcoming conferences

Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
– 10th European Life Science CEO Forum
– Redeye – Fight Cancer Seminar
– 11th Annual BIO-Equity Spring 2017 Conference

Targovax ASA: Fourth quarter and full year 2016 results

Oslo, Norway, 16 February 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.

A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).

Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway

Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).

International press event created attention all over Europe

Early September Oslo Cancer Cluster hosted an international press event with our member Abbvie. Over 20 journalists from all over Europe came to the Oslo Cancer Cluster Incubator and Innovatiion Park to learn more about the latest technological and scientific developments within cancer research.   The journalists attended a full day meeting at the Innovation […]

Joe Biden is looking to Norway

Vicepresident Joe Biden used Norway as an example when he spoke at the Social Good Summit this week. Biden was appointed by Barack Obama to lead the “Cancer Moonshot” project. The project aims to make a decade’s worth of advances in cancer prevention, diagnosis, treatment, and care in just 5 years.